

# Scott M Grundy

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8596839/scott-m-grundy-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

198  
papers

76,724  
citations

100  
h-index

230  
g-index

230  
ext. papers

87,418  
ext. citations

9.7  
avg, IF

7.97  
L-index

#	Paper	IF	Citations
198	Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. <i>Circulation</i> , <b>2009</b> , 120, 1640-5	16.7	8793
197	Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. <i>Circulation</i> , <b>2005</b> , 112, 2735-52	16.7	8005
196	Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. <i>Circulation</i> , <b>2004</b> , 110, 227-39	16.7	4450
195	The metabolic syndrome. <i>Lancet, The</i> , <b>2005</b> , 365, 1415-28	40	4380
194	Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. <i>Circulation</i> , <b>2004</b> , 109, 433-8	16.7	3857
193	Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. <i>Hepatology</i> , <b>2004</b> , 40, 1387-95	11.2	2757
192	Intensive lipid lowering with atorvastatin in patients with stable coronary disease. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 1425-35	59.2	2591
191	Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). <i>JAMA - Journal of the American Medical Association</i> , <b>1993</b> , 269, 3015	27.4	1589
190	Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. <i>Circulation</i> , <b>1999</b> , 100, 1134-46	16.7	1470
189	Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. <i>JAMA - Journal of the American Medical Association</i> , <b>2001</b> , 286, 180-7	27.4	1429
188	AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. <i>Circulation</i> , <b>2006</b> , 113, 2363-72	16.7	1395
187	AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. <i>Circulation</i> , <b>2002</b> , 105, 388-91	16.7	1349
186	AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. <i>Circulation</i> , <b>2011</b> , 124, 2458-73	16.7	1087
185	Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 44, 720-32	15.1	1070
184	Metabolic syndrome pandemic. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2008</b> , 28, 629-36	9.4	988
183	Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 2982-3021	15.1	922
182	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, e285-e350	15.1	895

181	Obesity, metabolic syndrome, and cardiovascular disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 2595-600	5.6	872
180	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , <b>2019</b> , 139, e1082-e1143	16.7	836
179	Efficacy and Safety of Plant Stanols and Sterols in the Management of Blood Cholesterol Levels. <i>Mayo Clinic Proceedings</i> , <b>2003</b> , 78, 965-978	6.4	759
178	ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Coronary Artery Calcium Scoring by Computed Tomography) in collaboration with the Society of	15.1	753
177	The metabolic syndrome. <i>Lancet, The</i> , <b>2010</b> , 375, 181-3	4.0	720
176	HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. <i>New England Journal of Medicine</i> , <b>1988</b> , 319, 24-33	59.2	663
175	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 3168-3209	15.1	654
174	Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 316, 1289-97	27.4	614
173	Comparison of monounsaturated fatty acids and carbohydrates for lowering plasma cholesterol. <i>New England Journal of Medicine</i> , <b>1986</b> , 314, 745-8	59.2	605
172	AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the European Society of Cardiology. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 58, 2543-2639	15.1	574
171	American College of Cardiology/American Heart Association Expert Consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. <i>Circulation</i> , <b>2000</b> , 102, 126-40	16.7	565
170	Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2004</b> , 24, e13-8	9.4	538
169	Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. <i>Circulation</i> , <b>2004</b> , 109, 2818-25	16.7	508
168	ACC/AHA/NHLBI clinical advisory on the use and safety of statins. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 40, 567-72	15.1	504
167	Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. <i>Diabetes Care</i> , <b>2004</b> , 27, 256-63	14.6	479
166	National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. <i>Journal of Clinical Lipidology</i> , <b>2015</b> , 9, 129-69	4.9	478
165	Metabolic syndrome: a multiplex cardiovascular risk factor. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 92, 399-404	5.6	466
164	AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. <i>Circulation</i> , <b>2001</b> , 104, 1577-9	16.7	464

163	Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 47, 1093-100	15.1	441
162	Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. <i>Archives of Internal Medicine</i> , <b>2002</b> , 162, 1568-76		432
161	Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. <i>Diabetes Care</i> , <b>2006</b> , 29, 1220-6	14.6	410
160	ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. <i>Circulation</i> , <b>2002</b> , 106, 1024-8	16.7	410
159	ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Pre-diabetes, metabolic syndrome, and cardiovascular risk). <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, 635-43	16.7	399
158	Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 308, 1150-9	15.1	386
157	Metabolic syndrome update. <i>Trends in Cardiovascular Medicine</i> , <b>2016</b> , 26, 364-73	27.4	385
156	Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. <i>American Journal of Cardiology</i> , <b>1998</b> , 81, 18B-25B	6.9	378
155	Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 485-94	3	378
154	Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. <i>Circulation</i> , <b>2008</b> , 117, 3002-9	15.1	372
153	Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 1810-5	16.7	357
152	AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. <i>Journal of the American College of Cardiology</i> , <b>1999</b> , 34, 1348-59	11.5	344
151	Genetic variants influencing circulating lipid levels and risk of coronary artery disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2010</b> , 30, 2264-76	15.1	319
150	Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. <i>Lancet, The</i> , <b>2006</b> , 368, 919-28	9.4	318
149	Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. <i>Mayo Clinic Proceedings</i> , <b>2003</b> , 78, 965-78	4.0	315
148	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. <i>Journal of Clinical Lipidology</i> , <b>2015</b> , 9, S1-122.e1	6.4	297
147	Plant sterols as cholesterol-lowering agents: clinical trials in patients with hypercholesterolemia and studies of sterol balance. <i>Atherosclerosis</i> , <b>1977</b> , 28, 325-38	4.9	293
146		3.1	282

145	American College of Cardiology/American Heart Association Expert Consensus Document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. <i>Journal of the American College of Cardiology</i> , <b>2000</b> , 36, 326-40	15.1	276
144	Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. <i>Obesity</i> , <b>2013</b> , 21, E439-47	8	263
143	Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). <i>American Journal of Cardiology</i> , <b>2005</b> , 95, 462-8	3	257
142	Ethnic differences in hepatic steatosis: an insulin resistance paradox?. <i>Hepatology</i> , <b>2009</b> , 49, 791-801	11.2	252
141	Approach to lipoprotein management in 2001 National Cholesterol Guidelines. <i>American Journal of Cardiology</i> , <b>2002</b> , 90, 11i-21i	3	251
140	An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report. <i>Journal of Clinical Lipidology</i> , <b>2014</b> , 8, 29-60	4.9	246
139	Cholesterol and Coronary Heart Disease. <i>JAMA - Journal of the American Medical Association</i> , <b>1986</b> , 256, 2849	27.4	237
138	Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. <i>Circulation</i> , <b>2002</b> , 106, 2526-9	16.7	230
137	Influence of body fat content and distribution on variation in metabolic risk. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2006</b> , 91, 4459-66	5.6	226
136	Transport of very low density lipoprotein triglycerides in varying degrees of obesity and hypertriglyceridemia. <i>Journal of Clinical Investigation</i> , <b>1979</b> , 63, 1274-83	15.9	226
135	Diagnosis and Management of the Metabolic Syndrome. <i>Circulation</i> , <b>2005</b> , 112,	16.7	217
134	Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. <i>Circulation</i> , <b>1997</b> , 95, 1-4	16.7	217
133	Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. <i>American Journal of Cardiology</i> , <b>2006</b> , 98, 1363-8	3	215
132	Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia. <i>Journal of Lipid Research</i> , <b>1972</b> , 13, 531-551	6.3	215
131	A Physiological Method for Estimation of Hepatic Secretion of Biliary Lipids in Man. <i>Gastroenterology</i> , <b>1972</b> , 62, 1200-1217	13.3	211
130	AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. <i>Journal of the American College of Cardiology</i> , <b>2001</b> , 38, 1581-3	15.1	210
129	Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. <i>Nature Reviews Drug Discovery</i> , <b>2006</b> , 5, 295-309	64.1	195
128	Chylomicron clearance in normal and hyperlipidemic man. <i>Metabolism: Clinical and Experimental</i> , <b>1976</b> , 25, 1225-39	12.7	194

127	Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. <i>Diabetes Care</i> , <b>2005</b> , 28, 1916-21	14.6	189
126	Fibric acids: effects on lipids and lipoprotein metabolism. <i>American Journal of Medicine</i> , <b>1987</b> , 83, 9-20	2.4	175
125	Dietary βsitosterol as an internal standard to correct for cholesterol losses in sterol balance studies. <i>Journal of Lipid Research</i> , <b>1968</b> , 9, 374-387	6.3	173
124	Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. <i>Circulation</i> , <b>2006</b> , 113, 38-43	16.7	165
123	Primary prevention of coronary heart disease: integrating risk assessment with intervention. <i>Circulation</i> , <b>1999</b> , 100, 988-98	16.7	164
122	Insulin resistance and body fat distribution in South Asian men compared to Caucasian men. <i>PLoS ONE</i> , <b>2007</b> , 2, e812	3.7	160
121	The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 1050-67	15.1	158
120	African Americans and Caucasians have a similar prevalence of coronary calcium in the Dallas Heart Study. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 44, 1011-7	15.1	158
119	Statin trials and goals of cholesterol-lowering therapy. <i>Circulation</i> , <b>1998</b> , 97, 1436-9	16.7	156
118	Relationship of anterior and posterior subcutaneous abdominal fat to insulin sensitivity in nondiabetic men. <i>Obesity</i> , <b>1997</b> , 5, 93-9		154
117	No association between plasma levels of plant sterols and atherosclerosis in mice and men. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2004</b> , 24, 2326-32	9.4	146
116	Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. <i>American Journal of Cardiology</i> , <b>2003</b> , 91, 956-60	3	145
115	Adipose tissue metabolites and insulin resistance in nondiabetic Asian Indian men. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 2750-5	5.6	141
114	Metabolic complications of obesity. <i>Endocrine</i> , <b>2000</b> , 13, 155-65		139
113	The association of differing measures of overweight and obesity with prevalent atherosclerosis: the Dallas Heart Study. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 50, 752-9	15.1	130
112	Does a diagnosis of metabolic syndrome have value in clinical practice?. <i>American Journal of Clinical Nutrition</i> , <b>2006</b> , 83, 1248-51	7	123
111	Does the metabolic syndrome exist?. <i>Diabetes Care</i> , <b>2006</b> , 29, 1689-92; discussion 1693-6	14.6	121
110	Hepatic lipase activity is lower in African American men than in white American men: effects of 5' flanking polymorphism in the hepatic lipase gene (LIPC). <i>Journal of Lipid Research</i> , <b>1998</b> , 39, 228-232	6.3	121

109	Harmonizing the definition of the metabolic syndrome: comparison of the criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European populations. <i>American Journal of Cardiology</i> , <b>2007</b> , 99, 541-8	3	114
108	Sex differences in the relationship between C-reactive protein and body fat. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 3251-8	5.6	108
107	An assessment by the Statin Intolerance Panel: 2014 update. <i>Journal of Clinical Lipidology</i> , <b>2014</b> , 8, S72-81.9	4.9	107
106	Adipose tissue and metabolic syndrome: too much, too little or neither. <i>European Journal of Clinical Investigation</i> , <b>2015</b> , 45, 1209-17	4.6	100
105	Genetic polymorphism PC-1 K121Q and ethnic susceptibility to insulin resistance. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 5927-34	5.6	100
104	Diet composition and the metabolic syndrome: what is the optimal fat intake?. <i>American Journal of Medicine</i> , <b>2002</b> , 113 Suppl 9B, 25S-29S	2.4	100
103	An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia. <i>Journal of Clinical Lipidology</i> , <b>2013</b> , 7, 561-5	4.9	94
102	Elevated plasma high-sensitivity C-reactive protein concentrations in Asian Indians living in the United States. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 3773-6	5.6	92
101	United States Cholesterol Guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy. <i>American Journal of Cardiology</i> , <b>2001</b> , 88, 23J-27J	3	84
100	Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2007</b> , 27, 2043-9	9.4	83
99	Coronary plaque as a replacement for age as a risk factor in global risk assessment. <i>American Journal of Cardiology</i> , <b>2001</b> , 88, 8E-11E	3	77
98	Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , <b>2018</b> , 138, 2315-2325	16.7	75
97	Effects of sucrose polyester on cholesterol metabolism in man. <i>Metabolism: Clinical and Experimental</i> , <b>1979</b> , 28, 994-1000	12.7	75
96	Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentrations or turnover. <i>Journal of Pediatrics</i> , <b>1988</b> , 113, 387-92	3.6	72
95	The metabolic syndrome: a practical guide to origins and treatment: Part II. <i>Circulation</i> , <b>2003</b> , 108, 1537-46.7	46.7	68
94	Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance. <i>Clinical Cornerstone</i> , <b>2006</b> , 8 Suppl 1, S21-7		65
93	Metabolic correlates of nonalcoholic fatty liver in women and men. <i>Hepatology</i> , <b>2007</b> , 46, 716-22	11.2	64
92	Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2010</b> , 95, 800-9	5.6	61

91	Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). <i>American Journal of Cardiology</i> , <b>2005</b> , 95, 194-8	3	60
90	Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. <i>Current Opinion in Lipidology</i> , <b>1996</b> , 7, 209-16	4.4	59
89	Metabolic risk susceptibility in men is partially related to adiponectin/leptin ratio. <i>Journal of Obesity</i> , <b>2013</b> , 2013, 409679	3.7	58
88	Sex differences in the association between leptin and CRP: results from the Dallas Heart Study. <i>Atherosclerosis</i> , <b>2007</b> , 195, 404-10	3.1	56
87	Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). <i>American Journal of Cardiology</i> , <b>2009</b> , 103, 1694-702	3	55
86	What is the contribution of obesity to the metabolic syndrome?. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2004</b> , 33, 267-82, table of contents	5.5	54
85	Cardiorespiratory fitness and metabolic risk. <i>American Journal of Cardiology</i> , <b>2012</b> , 109, 988-93	3	51
84	Point: the metabolic syndrome still lives. <i>Clinical Chemistry</i> , <b>2005</b> , 51, 1352-4	5.5	51
83	2013 ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 64, 601-12	15.1	50
82	Overnutrition, ectopic lipid and the metabolic syndrome. <i>Journal of Investigative Medicine</i> , <b>2016</b> , 64, 1082-6	6	48
81	Independent associations between metabolic syndrome, diabetes mellitus and atherosclerosis: observations from the Dallas Heart Study. <i>Diabetes and Vascular Disease Research</i> , <b>2008</b> , 5, 96-101	3.3	48
80	Stanol esters as a component of maximal dietary therapy in the National Cholesterol Education Program Adult Treatment Panel III report. <i>American Journal of Cardiology</i> , <b>2005</b> , 96, 47D-50D	3	48
79	A constellation of complications: the metabolic syndrome. <i>Clinical Cornerstone</i> , <b>2005</b> , 7, 36-45		48
78	Hepatic lipase (LIPC) promoter polymorphism in men with coronary artery disease. Allele frequency and effects on hepatic lipase activity and plasma HDL-C concentrations. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1999</b> , 19, 1975-8	9.4	48
77	Body mass index and hepatic lipase gene (LIPC) polymorphism jointly influence postheparin plasma hepatic lipase activity. <i>Journal of Lipid Research</i> , <b>1998</b> , 39, 1127-1130	6.3	46
76	Waist circumference as measure of abdominal fat compartments. <i>Journal of Obesity</i> , <b>2013</b> , 2013, 454285	3.7	44
75	Accumulation of 7 alpha-hydroxy-4-cholesten-3-one and cholesta-4,6-dien-3-one in patients with cerebrotendinous xanthomatosis: effect of treatment with chenodeoxycholic acid. <i>Hepatology</i> , <b>1987</b> , 7, 266-71	11.2	44
74	The possible role of the arterial microcirculation in the pathogenesis of atherosclerosis. <i>Journal of Chronic Diseases</i> , <b>1980</b> , 33, 679-84		37



73	Next Steps in Primary Prevention of Coronary Heart Disease: Rationale for and Design of the ECAD Trial. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 1828-1836	15.1	36
72	Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers. <i>PLoS ONE</i> , <b>2014</b> , 9, e114519	3.7	34
71	Promise of low-density lipoprotein-lowering therapy for primary and secondary prevention. <i>Circulation</i> , <b>2008</b> , 117, 569-73; discussion 573	16.7	34
70	Can we dramatically reduce the incidence of coronary heart disease?. <i>Nature Reviews Cardiology</i> , <b>2011</b> , 8, 721-5	14.8	33
69	Does Dietary Cholesterol Matter?. <i>Current Atherosclerosis Reports</i> , <b>2016</b> , 18, 68	6	31
68	Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial). <i>American Journal of Cardiology</i> , <b>2009</b> , 104, 548-53	3	31
67	Cardiovascular and metabolic risk factors: how can we improve outcomes in the high-risk patient?. <i>American Journal of Medicine</i> , <b>2007</b> , 120, S3-8; discussion S9	2.4	30
66	Non-high-density lipoprotein cholesterol level as potential risk predictor and therapy target. <i>Archives of Internal Medicine</i> , <b>2001</b> , 161, 1379-80		30
65	Variable contributions of fat content and distribution to metabolic syndrome risk factors. <i>Metabolic Syndrome and Related Disorders</i> , <b>2008</b> , 6, 281-8	2.6	29
64	2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline. <i>Annals of Internal Medicine</i> , <b>2019</b> , 170, 779-783	8	27
63	Effects of AOMA on cholesterol metabolism in man. <i>Metabolism: Clinical and Experimental</i> , <b>1982</b> , 31, 733-9	12.7	26
62	Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial). <i>American Journal of Cardiology</i> , <b>2011</b> , 108, 40-6	3	25
61	Three polymorphisms associated with low hepatic lipase activity are common in African Americans. <i>Journal of Lipid Research</i> , <b>1998</b> , 39, 1900-1903	6.3	25
60	Cardiorespiratory fitness, LDL cholesterol, and CHD mortality in men. <i>Medicine and Science in Sports and Exercise</i> , <b>2012</b> , 44, 2132-7	1.2	22
59	2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterol-Secondary Prevention. <i>JAMA Cardiology</i> , <b>2019</b> , 4, 589-591	16.2	21
58	Statin therapy in older persons: pertinent issues. <i>Archives of Internal Medicine</i> , <b>2002</b> , 162, 1329-31		21
57	Oxidized LDL and atherogenesis: relation to risk factors for coronary heart disease. <i>Clinical Cardiology</i> , <b>1993</b> , 16, 13-5	3.3	20
56	Effect of colesvelam hydrochloride on glycemia and insulin sensitivity in men with the metabolic syndrome. <i>American Journal of Cardiology</i> , <b>2011</b> , 108, 1129-35	3	18

55	Clinical characteristics, vascular function, and inflammation in women with angina in the absence of coronary atherosclerosis: the Dallas Heart Study. <i>JACC: Cardiovascular Imaging</i> , <b>2011</b> , 4, 65-73	8.4	17
54	Metabolic Concomitants of Obese and Nonobese Women With Features of Polycystic Ovarian Syndrome. <i>Journal of the Endocrine Society</i> , <b>2017</b> , 1, 1417-1427	0.4	16
53	Dietary fat: at the heart of the matter. <i>Science</i> , <b>2001</b> , 293, 801-4	33.3	16
52	Influence of upper and lower body adipose tissue on insulin sensitivity in South Asian men. <i>Journal of Investigative Medicine</i> , <b>2012</b> , 60, 999-1004	2.9	15
51	A changing paradigm for prevention of cardiovascular disease: emergence of the metabolic syndrome as a multiplex risk factor. <i>Country Review Ukraine</i> , <b>2008</b> , 10, B16-B23		15
50	Recent nutrition research: implications for foods of the future. <i>Annals of Medicine</i> , <b>1991</b> , 23, 187-93	1.5	15
49	The 2018 AHA/ACC/Multi-Society Cholesterol guidelines: Looking at past, present and future. <i>Progress in Cardiovascular Diseases</i> , <b>2019</b> , 62, 375-383	8.5	15
48	Upper body fat predicts metabolic syndrome similarly in men and women. <i>European Journal of Clinical Investigation</i> , <b>2018</b> , 48, e12941	4.6	14
47	The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol in Diabetes. <i>Diabetes Care</i> , <b>2020</b> , 43, 1673-1678	14.6	14
46	Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? Yes. <i>BMJ, The</i> , <b>2007</b> , 334, 982	5.9	13
45	2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol: Primary Prevention. <i>JAMA Cardiology</i> , <b>2019</b> , 4, 488-489	16.2	12
44	Ethnic and gender susceptibility to metabolic risk. <i>Metabolic Syndrome and Related Disorders</i> , <b>2014</b> , 12, 110-6	2.6	11
43	Is There a Gradient of Mortality Risk among Men with Low Cardiorespiratory Fitness?. <i>Medicine and Science in Sports and Exercise</i> , <b>2015</b> , 47, 1825-32	1.2	11
42	Relationship of apolipoprotein B levels to the number of risk factors for metabolic syndrome. <i>Journal of Investigative Medicine</i> , <b>2007</b> , 55, 237-47	2.9	11
41	Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 712-714	15.1	10
40	Current trends in non-HDL cholesterol and LDL cholesterol levels in adults with atherosclerotic cardiovascular disease. <i>Journal of Clinical Lipidology</i> , <b>2019</b> , 13, 563-567	4.9	10
39	Plasma noncholesterol sterols as indicators of cholesterol absorption. <i>Journal of Lipid Research</i> , <b>2013</b> , 54, 873-5	6.3	10
38	An Analysis of Individual Body Fat Depots and Risk of Developing Cancer: Insights From the Dallas Heart Study. <i>Mayo Clinic Proceedings</i> , <b>2017</b> , 92, 536-543	6.4	8

37	Evaluation of coronary artery calcium screening strategies focused on risk categories: the Dallas Heart Study. <i>American Heart Journal</i> , <b>2009</b> , 157, 1001-9	4.9	8
36	Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men. <i>Journal of Clinical Lipidology</i> , <b>2016</b> , 10, 1414-1422.e1	4.9	7
35	Dyslipidaemia in 2015: Advances in treatment of dyslipidaemia. <i>Nature Reviews Cardiology</i> , <b>2016</b> , 13, 74-5	14.8	7
34	Cholesterol management in patients with heart disease. Emphasizing secondary prevention to increase longevity. <i>Postgraduate Medicine</i> , <b>1997</b> , 102, 81-4, 87-90	3.7	7
33	Alternative approaches to cholesterol-lowering therapy. <i>American Journal of Cardiology</i> , <b>2002</b> , 90, 1135-8		7
32	Atherosclerosis imaging for risk assessment and primary prevention of cardiovascular disease. <i>Progress in Cardiovascular Diseases</i> , <b>2003</b> , 46, 115-21	8.5	7
31	Cholesterol management in older persons. <i>American Journal of Medicine</i> , <b>2014</b> , 127, 1140-1	2.4	6
30	Impaired hepatic ketogenesis in moderately obese men with hypertriglyceridemia. <i>Journal of Investigative Medicine</i> , <b>2009</b> , 57, 590-4	2.9	6
29	Fatty acid oxidation in normotriglyceridemic men. <i>Journal of Clinical Lipidology</i> , <b>2016</b> , 10, 283-8	4.9	6
28	Statins: definitive translational research. <i>Molecular Medicine</i> , <b>2014</b> , 20 Suppl 1, S20-3	6.2	5
27	Scavenger Receptor B-1 Emerges as Anti-atherogenic Candidate. <i>Cell Metabolism</i> , <b>2016</b> , 23, 755-7	24.6	5
26	Thyroid mimetic as an option for lowering low-density lipoprotein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 409-10	11.5	4
25	Cholesterol management in high-risk patients without heart disease. When is lipid-lowering medication warranted for primary prevention?. <i>Postgraduate Medicine</i> , <b>1998</b> , 104, 117-20, 123-4, 129	3.7	4
24	Comparison of the effects of guanabenz and hydrochlorothiazide on plasma lipids. <i>Clinical Pharmacology and Therapeutics</i> , <b>1988</b> , 44, 297-302	6.1	4
23	Treatment targets in the management of dyslipidemias: which targets in whom?. <i>Current Cardiology Reports</i> , <b>2012</b> , 14, 692-700	4.2	3
22	Metabolic syndrome phenotype in very obese women. <i>Metabolic Syndrome and Related Disorders</i> , <b>2007</b> , 5, 3-12	2.6	3
21	Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review.. <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 819-836	15.1	3
20	Reply: Statin dose based on limited evidence. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 760-1	15.1	2

19	Metabolic syndrome: what is it and how should I treat it?. <i>ACC Current Journal Review</i> , <b>2003</b> , 12, 37-40		2
18	Treatment of diabetic dyslipidaemia. <i>Biochemical Society Transactions</i> , <b>1989</b> , 17, 56-8	5.1	2
17	Cholesterol and coronary heart disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>1990</b> , 199, 17-24	2	2
16	Four Cases of Cholesterol Management Informed by the 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol. <i>JAMA Cardiology</i> , <b>2019</b> , 4, 473-477	16.2	1
15	Temporal decline in non-high-density lipoprotein cholesterol in subjects with diabetes mellitus without atherosclerotic cardiovascular disease. <i>Journal of Clinical Lipidology</i> , <b>2020</b> , 14, 425-430	4.9	1
14	Treating Hypercholesterolemia in Older Adults. <i>JAMA - Journal of the American Medical Association</i> , <b>2019</b> , 322, 695	27.4	1
13	Combination of fenofibrate plus low-dose nicotinic acid added to statin treatment in type 2 diabetes: An open-label, crossover study. <i>Current Therapeutic Research</i> , <b>2006</b> , 67, 321-33	2.4	1
12	Drug Therapy in Dyslipidemia. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , <b>1990</b> , 50, 63-72	2	1
11	Utility of metabolic syndrome as a risk enhancing factor in decision of statin use. <i>Journal of Clinical Lipidology</i> , <b>2021</b> , 15, 255-265	4.9	1
10	Chronic kidney disease and statin eligibility. <i>Journal of Clinical Lipidology</i> , <b>2021</b> , 15, 173-180	4.9	1
9	Coronary Artery Calcium: Where Do We Stand After Over 3 Decades?. <i>American Journal of Medicine</i> , <b>2021</b> , 134, 1091-1095	2.4	1
8	High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. <i>Mayo Clinic Proceedings</i> , <b>2021</b> , 96, 2660-2670	6.4	1
7	Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) guidelines for management of dyslipidemia and cardiovascular disease risk reduction: Putting evidence in context. <i>Progress in Cardiovascular Diseases</i> , <b>2021</b> , 68, 2-6	8.5	0
6	Perspectives on Cholesterol Guidelines. <i>Contemporary Endocrinology</i> , <b>2015</b> , 313-327	0.3	
5	Cholesterol Management in the Context of Risk Factor Profile 187-195		
4	TNT Trial <b>2008</b> , 1		
3	Reply to AM Zivkovic and JB German. <i>American Journal of Clinical Nutrition</i> , <b>2007</b> , 85, 241-242	7	
2	Reply to ML Goldberg and MG Enig. <i>American Journal of Clinical Nutrition</i> , <b>1993</b> , 58, 244-244	7	

- 1 Management of Cholesterol Disorders **2007**, 2667-2691